{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:57:04Z","timestamp":1760623024367,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim Care Resp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis was to examine real-life prescribing of first maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum Patient Care Research Database for patients with a first prescription for COPD maintenance therapy between 2009 and 2012 and a diagnosis of COPD at or before the date of the first prescription for COPD maintenance therapy. Routine clinical data including demographics, disease history and symptoms, comorbidities, therapy, hospitalisation rate and exacerbation rate were collected and used to characterise patients stratified by disease severity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group (A\u2013D). The analysis population included 2,217 individuals (55.4% male, 45.2% smokers). Long-acting muscarinic antagonists (LAMA) as monotherapy were prescribed as first maintenance therapy for 40.2% of patients. ICS were prescribed as ICS\/long-acting beta-agonists combination for 29.1% of patients or as monotherapy for 15.5%. ICS (alone or in combination) were prescribed to &gt;40% of patients in each GOLD group. ICS-containing regimens were prescribed to patients with a history of pneumonia and comorbid conditions for whom the risks of ICS therapy may outweigh the benefits. The clinical reality of prescribing indicates that ICS are often prescribed outside current guideline recommendations for many patients newly diagnosed with COPD in the UK. Encouragingly, LAMAs are increasingly being prescribed as first maintenance therapy for these patients.<\/jats:p>","DOI":"10.1038\/npjpcrm.2016.61","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T10:03:35Z","timestamp":1478167415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis"],"prefix":"10.1038","volume":"26","author":[{"given":"David","family":"Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Haughney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsiaryna","family":"Bichel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"BFnpjpcrm201661_CR1","unstructured":"Health and Safety Executive. Chronic Obstructive Pulmonary Disease (COPD) in Great Britain (2013). Available at www.hse.gov.uk\/statistics\/causdis\/copd\/. Accessed on 11 October 2015."},{"key":"BFnpjpcrm201661_CR2","unstructured":"National Institute for Health and Care Excellence. NICE pathways. COPD. Available at http:\/\/pathways.nice.org.uk\/pathways\/chronic-obstructive-pulmonary-disease#content=view-node%3Anodes-referral-for-specialist-advice. Accessed on 11 October 2016."},{"key":"BFnpjpcrm201661_CR3","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Available at http:\/\/goldcopd.org\/global-strategy-diagnosis-management-prevention-copd-2016\/. Accessed on 11 October 2016."},{"key":"BFnpjpcrm201661_CR4","unstructured":"National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Available at http:\/\/guidance.nice.org.uk\/CG101\/Guidance\/pdf\/English. Accessed on 11 October 2016."},{"key":"BFnpjpcrm201661_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","volume":"22","author":"D Price","year":"2013","unstructured":"Price, D., Yawn, B., Brusselle, G. & Rossi, A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 22, 92\u2013100 (2013).","journal-title":"Prim. Care Respir. J."},{"issue":"2 Suppl","key":"BFnpjpcrm201661_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1586\/ers.13.14","volume":"7","author":"E Anton","year":"2013","unstructured":"Anton, E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev. Respir. Med. 7 (2 Suppl), 25\u201332 (2013).","journal-title":"Expert Rev. Respir. Med."},{"key":"BFnpjpcrm201661_CR7","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/thoraxjnl-2013-203773","volume":"68,","author":"I Sabroe","year":"2013","unstructured":"Sabroe, I., Postma, D., Heijink, I. & Dockrell, D. H. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax 68, 1085\u20131087 (2013).","journal-title":"Thorax"},{"key":"BFnpjpcrm201661_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1465-9921-9-62","volume":"9","author":"RC Jones","year":"2008","unstructured":"Jones, R. C., Dickson-Spillmann, M., Mather, M. J., Marks, D. & Shackell, B. S. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir. Res. 9, 62\u201369 (2008).","journal-title":"Respir. Res."},{"key":"BFnpjpcrm201661_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.rmed.2012.03.008","volume":"106,","author":"A Corrado","year":"2012","unstructured":"Corrado, A. & Rossi, A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir. Med. 106, 989\u2013997 (2012).","journal-title":"Respir. Med."},{"key":"BFnpjpcrm201661_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2296-15-42","volume":"15","author":"E Drivenes","year":"2014","unstructured":"Drivenes, E., Ostrem, A. & Melbye, H. Predictors of ICS\/LABA prescribing in COPD patients: a study from general practice. BMC Fam. Pract. 15, 42 (2014).","journal-title":"BMC Fam. Pract."},{"key":"BFnpjpcrm201661_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.rmr.2009.08.002","volume":"27","author":"G Jebrak","year":"2010","unstructured":"Jebrak, G. [COPD routine management in France: are guidelines used in clinical practice?]. Rev. Mal. Respir. 27, 11\u201318 (2010).","journal-title":"Rev. Mal. Respir."},{"issue":"w13053","key":"BFnpjpcrm201661_CR12","first-page":"1","volume":"140","author":"A Jochmann","year":"2010","unstructured":"Jochmann, A. et al. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med. Wkly. 140 (w13053), 1\u20138 (2010).","journal-title":"Swiss Med. Wkly."},{"key":"BFnpjpcrm201661_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/COPD.S62750","volume":"9","author":"D Price","year":"2014","unstructured":"Price, D. et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 889\u2013904 (2014).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"BFnpjpcrm201661_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3109\/15412555.2013.839646","volume":"11","author":"M Di Martino","year":"2014","unstructured":"Di Martino, M. et al. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study. COPD 11, 414\u2013423 (2014).","journal-title":"COPD"},{"key":"BFnpjpcrm201661_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1185\/03007995.2011.583230","volume":"27","author":"K Fitch","year":"2011","unstructured":"Fitch, K., Iwasaki, K., Pyenson, B., Plauschinat, C. & Zhang, J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr. Med. Res. Opin. 27, 1425\u20131429 (2011).","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnpjpcrm201661_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.rmed.2007.02.019","volume":"101,","author":"M Miravitlles","year":"2007","unstructured":"Miravitlles, M. et al. Use of spirometry and patterns of prescribing in COPD in primary care. Respir. Med. 101, 1753\u20131760 (2007).","journal-title":"Respir. Med."},{"key":"BFnpjpcrm201661_CR17","doi-asserted-by":"publisher","first-page":"e75221","DOI":"10.1371\/journal.pone.0075221","volume":"8","author":"P White","year":"2013","unstructured":"White, P., Thornton, H., Pinnock, H., Georgopoulou, S. & Booth, H. P. Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study. PLoS ONE 8, e75221 (2013).","journal-title":"PLoS ONE"},{"key":"BFnpjpcrm201661_CR18","first-page":"2207","volume":"10","author":"G Brusselle","year":"2015","unstructured":"Brusselle, G. et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2207\u20132217 (2015).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"BFnpjpcrm201661_CR19","first-page":"2439","volume":"10","author":"M Kerkhof","year":"2015","unstructured":"Kerkhof, M., Freeman, D., Jones, R., Chisholm, A. & Price, D. B. Predicting frequent COPD exacerbations using primary care data. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2439\u20132450 (2015).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"BFnpjpcrm201661_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775\u2013789 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnpjpcrm201661_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/thx.2011.160028","volume":"66","author":"YK Loke","year":"2011","unstructured":"Loke, Y. K., Cavallazzi, R. & Singh, S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66, 699\u2013708 (2011).","journal-title":"Thorax"},{"key":"BFnpjpcrm201661_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/MCP.0b013e328334c085","volume":"16","author":"S Singh","year":"2010","unstructured":"Singh, S. & Loke, Y. K. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr. Opin. Pulm. Med. 16, 118\u2013122 (2010).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"BFnpjpcrm201661_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1183\/13993003\/erj.42.6.E36","volume":"42","author":"A Agusti","year":"2013","unstructured":"Agusti A. et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur. Respir. J. 42, 36\u2013646 (2013).","journal-title":"Eur. Respir. J."},{"key":"BFnpjpcrm201661_CR24","doi-asserted-by":"publisher","first-page":"e97149","DOI":"10.1371\/journal.pone.0097149","volume":"9","author":"RL DiSantostefano","year":"2014","unstructured":"DiSantostefano, R. L. et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS ONE 9, e97149 (2014).","journal-title":"PLoS ONE"},{"key":"BFnpjpcrm201661_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40265-014-0202-z","volume":"74,","author":"K Mattishent","year":"2014","unstructured":"Mattishent, K. et al. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs 74, 539\u2013547 (2014).","journal-title":"Drugs"},{"key":"BFnpjpcrm201661_CR26","first-page":"CD010115","volume":"3","author":"KM Kew","year":"2014","unstructured":"Kew, K. M. & Seniukovich, A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 3, CD010115 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnpjpcrm201661_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","volume":"68","author":"S Suissa","year":"2013","unstructured":"Suissa, S., Patenaude, V., Lapi, F. & Ernst, P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68, 1029\u20131036 (2013).","journal-title":"Thorax"},{"key":"BFnpjpcrm201661_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1164\/rccm.200307-926OC","volume":"169","author":"TA Lee","year":"2004","unstructured":"Lee, T. A. & Weiss, K. B. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 169, 855\u2013859 (2004).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnpjpcrm201661_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00592-014-0584-0","volume":"51","author":"P Rogliani","year":"2014","unstructured":"Rogliani, P., Calzetta, L., Segreti, A., Barrile, A. & Cazzola, M. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 51, 933\u2013940 (2014).","journal-title":"Acta Diabetol."},{"key":"BFnpjpcrm201661_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.amjmed.2008.09.048","volume":"122,","author":"CG Slatore","year":"2009","unstructured":"Slatore, C. G., Bryson, C. L. & Au, D. H. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am. J. Med. 122, 472\u2013478 (2009).","journal-title":"Am. J. Med."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201661.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201661","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201661.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:43:46Z","timestamp":1749685426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,1]]}},"alternative-id":["BFnpjpcrm201661"],"URL":"https:\/\/doi.org\/10.1038\/npjpcrm.2016.61","relation":{},"ISSN":["2055-1010"],"issn-type":[{"type":"electronic","value":"2055-1010"}],"subject":[],"published":{"date-parts":[[2016,11,3]]},"assertion":[{"value":"27 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DP has acted as a consultant for Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline (GSK), Meda, Mundipharma, Napp, Novartis, Pfizer and Teva. He has received research grants from the UK National Health Service, the British Lung Foundation, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GSK, Meda, Merck, Mundipharma, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva and Zentiva. He owns shares in AKL Ltd, which produced phytopharmaceuticals and owns 80% of RiRL Ltd and its subsidiary social enterprise Optimum Patient Care. He has received unrestricted funding for investigator-initiated studies from Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva and Zentiva. MM has received speaker fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, Esteve, GSK, Menarini, Grifols, Mycomed and Novartis, and has received consulting fees from Almirall, Boehringer Ingelheim, Pfizer, GSK, Gebro Pharma, CLS Behring, MedImmune, Novartis, Grifols and Nycomed. In the last 5 years, IP has received speaker\u2019s honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis and GSK, and a payment for organising an educational event for SPRs from AstraZeneca. He has received honoraria for attending advisory panels with Almirall, Genentech, Regeneron, AstraZeneca, Boehringer Ingelheim, GSK, Merck Sharp and Dohme (MSD), Schering-Plough, Novartis, Dey, Napp and Respivert. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca and Napp. Neither MT nor any member of his close family has any shares in pharmaceutical companies. In the last 3 years he has received speaker\u2019s honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: Aerocrine, AstraZeneca, Boehringer Ingelheim, GSK, MSD and Teva. He has received honoraria for attending advisory panels with Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, MSD and Novartis. He has received sponsorship to attend international scientific meetings from GSK, AstraZeneca and Mundipharma. He has received funding for research projects from GSK and Almirall. He is chief medical adviser to the charity Asthma UK, a member of the BTS SIGN Asthma guideline group and the NICE Asthma guideline group. JW has received research grants from GSK, Takeda, Almirall, Novartis, Johnson and Johnson and Vifor Pharma, honoraria for advisory boards for Almirall, Novartis, GSK, Boehringer, Takeda, Johnson and Johnson, Napp, Pfizer and AstraZeneca, and lecture\/presentation fees from Almirall, Novartis, GSK, Boehringer and Takeda. JH has received reimbursement for attending symposia, fees for speaking, organising educational events, funds for research or fees for consulting from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, MSD, Mundipharma, Novartis and Teva. KB and DW were employees of RiRL Ltd at the time of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16061"}}